RJA
BIOR

Raymond James & Associates’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Raymond James & Associates’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-88
Closed -$33K – 4331
2021
Q3 		$33K Hold
88
– – ﹤0.01% 3957
2021
Q2 		$79K Buy
+88
New +$67.3K ﹤0.01% 3872

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James & Associates's BIOR Position: Q4 2021 in Review

Raymond James & Associates sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2021, closing a stake of 88 shares — an estimated $33K sold.

Raymond James & Associates first reported a position in BIOR in Q2 2021 and held it in 2 quarters. The position peaked at $79K in Q2 2021. 53 funds tracked by Wall St. Rank hold BIOR as of Q4 2021.

  • Raymond James & Associates reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 88 Biora Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $33K.
  • Raymond James & Associates first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Raymond James & Associates's Biora Therapeutics, Inc. Common Stock position peaked at $79K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.